Updated results of a first-in-human dose-finding study of the ALK/EGFR inhibitor AP26113 in patients with advanced malignancies
JOURNAL OF THORACIC ONCOLOGY(2013)
关键词
NSCLC,ALK,EGFR,AP26113
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要
JOURNAL OF THORACIC ONCOLOGY(2013)